MDL105519 Inhibitor – MDL 105519

Solid. Powder

98.00%

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

376.19

DMSO: 17mg/mL (45.19mM) Need ultrasonic and warming
(<1mg/ml refers to the product slightly soluble or insoluble)

C18H11Cl2NO4

O=C(O)C(N1)=C(/C=C(C2=CC=CC=C2)/C(O)=O)C3=C1C=C(Cl)C=C3Cl

161230-88-2

Others

MDL 105519 is annMDA receptor antagonist in vivo. MDL 105519 (intravenously administration) prevents harmaline-stimulated increases in cerebellar cyclic GMP content, providing biochemical evidence of nMDA receptor antagonism in vivo. Anxiolytic activity is observed in the rat separation-induced vocalization model, but muscle-relaxant activity is apparent at lower doses. This antagonism is associated with anticonvulsant activity in genetically based, chemically induced, and electrically mediated seizure models. Higher doses impair rotorod performance but are without effect on mesolimbic dopamine turnover or prepulse inhibition of the startle reflex.